Difference between revisions of "Team:NCTU Formosa/Composite Part"
(49 intermediate revisions by 4 users not shown) | |||
Line 10: | Line 10: | ||
a, abbr, acronym, address, big, cite, code, | a, abbr, acronym, address, big, cite, code, | ||
del, dfn, em, font, img, ins, kbd, q, s, samp, | del, dfn, em, font, img, ins, kbd, q, s, samp, | ||
− | small, strike, strong | + | small, strike, strong, tt, var, |
b, u, i, center, | b, u, i, center, | ||
dl, dt, dd, ol, ul, li, | dl, dt, dd, ol, ul, li, | ||
Line 57: | Line 57: | ||
} | } | ||
.p01{ | .p01{ | ||
− | background-color:# | + | background-color:#FF6347; |
position:relative; | position:relative; | ||
height:70vh; | height:70vh; | ||
width:100%; | width:100%; | ||
left:0vw; | left:0vw; | ||
+ | opacity:0.8; | ||
} | } | ||
.p02{ | .p02{ | ||
Line 69: | Line 70: | ||
} | } | ||
.background1{ | .background1{ | ||
− | background-image:url("https://static.igem.org/mediawiki/2015/d/ | + | background-image:url("https://static.igem.org/mediawiki/2015/d/dd/NCTU_Formosa_E.cotector4.png"); |
background-repeat:no-repeat; | background-repeat:no-repeat; | ||
− | background-position:center; | + | background-position:center 12vh; |
position:relative; | position:relative; | ||
height:70vh; | height:70vh; | ||
width:40vw; | width:40vw; | ||
− | background-size: | + | background-size:55%; |
top:0vh; | top:0vh; | ||
left:10vw; | left:10vw; | ||
Line 86: | Line 87: | ||
position:relative; | position:relative; | ||
right:20vw; | right:20vw; | ||
− | top: | + | top:33vh; |
color:#fff; | color:#fff; | ||
z-index:100; | z-index:100; | ||
Line 92: | Line 93: | ||
text-align:center; | text-align:center; | ||
} | } | ||
− | |||
.content{ | .content{ | ||
font-family:Arial; | font-family:Arial; | ||
Line 141: | Line 141: | ||
font-size:20pt; | font-size:20pt; | ||
padding-top:2vh;} | padding-top:2vh;} | ||
+ | table { | ||
+ | border:0; | ||
+ | border-collpase:collpase; | ||
+ | } | ||
+ | td { | ||
+ | padding-top:10px; | ||
+ | padding-bottom:50px; | ||
+ | text-align: left; | ||
+ | font-family:Arial; | ||
+ | font-size:14pt; | ||
+ | LINE-HEIGHT:25pt; | ||
+ | } | ||
+ | .part{ | ||
+ | font-size:16pt; | ||
+ | } | ||
+ | .part a{ | ||
+ | font-size:16pt; | ||
+ | color:#0200FF; | ||
+ | text-decoration:none; | ||
+ | } | ||
+ | .part span{font-size:18pt;} | ||
+ | .reference{ | ||
+ | font-size:10pt; | ||
+ | position:relative; | ||
+ | border-top:#999 1px solid; | ||
+ | } | ||
+ | |||
+ | |||
+ | #groupparts { | ||
+ | margin: 0 auto; | ||
+ | background-color:#FCFCDE;} | ||
</style> | </style> | ||
Line 148: | Line 179: | ||
<div class="p01"> | <div class="p01"> | ||
<div class="background1"></div> | <div class="background1"></div> | ||
− | <div class="title"> | + | <div class="title">Composite Parts</div> |
</div> | </div> | ||
<div class="p02"> | <div class="p02"> | ||
− | <div class="content"></ | + | <div class="content"> |
+ | <h2>Composite Part</h2> | ||
+ | <table> | ||
+ | <tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr> | ||
+ | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694013">BBa_K1694013</a></span><br> | ||
+ | OmpA-anti-VEGF<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694014">BBa_K1694014</a></span><br> | ||
+ | OmpA-anti-EGFR<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694015">BBa_K1694015</a></span><br> | ||
+ | OmpA-anti-HER2<br> | ||
+ | </td><td></td><td>In order to change the scFv parts easily, we added a <i>Nco</i>I restriction site between OmpA and scFv so that we can change various scFv DNA sequence using the <i>Nco</i>I restriction enzyme.</td></tr> | ||
− | < | + | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694023">BBa_K1694023</a></span><br> |
− | <a href=" | + | P<sub>cons</sub>+RBS+OmpA-anti-VEGF<br> |
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694024">BBa_K1694024</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-EGFR<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694025">BBa_K1694025</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-HER2<br> | ||
+ | </td><td></td><td>By ligating the constitutive promoter (<a href="http://parts.igem.org/Part:BBa_J23101">BBa_J23101</a>), strong ribosome binding site (<a href="http://parts.igem.org/Part:BBa_B0034">BBa_B0034</a>) and Lpp-OmpA-scFv, we were able to display scFv on the <i>E.coli</i> outer membrane continuously. | ||
+ | Having this part, we can co-transform with other parts in order to produce color as the detection signal.<br><br> | ||
+ | |||
+ | In addition, by co-transforming these different types of <i>E.coli</i> with different fluorescence or color as signals, we are able to create a platform which can detect multimarker and consequently achieve combination therapy. | ||
+ | </td></tr> | ||
+ | |||
+ | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694033">BBa_K1694033</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-VEGF+RBS+GFP+Ter<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694034">BBa_K1694034</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-EGFR+RBS+GFP+Ter<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694035">BBa_K1694035</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-HER2+RBS+GFP+Ter<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694044">BBa_K1694044</a></span><br> | ||
+ | Pcons+RBS+OmpA-anti-EGFR+RBS+RFP+Ter<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694045">BBa_K1694045</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-HER2+RBS+BFP+Ter<br> | ||
+ | |||
+ | </td><td></td><td>The most commonly constructing way of composite parts is to ligate the required parts together. We also provide this kind of parts.<br> | ||
+ | At the back of the Lpp-OmpA-scFv part, we ligated the weaker ribosome biding site (<a href="網址">BBa_B0030</a>), different fluorescent protein and terminator (<a href="http://parts.igem.org/Part:BBa_J61048">BBa_J61048</a>) to make it continuously and simultaneously express the fluorescence and the scFv. We used a weak ribosome binding site to ensure that scFv's production will not be affected. | ||
+ | </td></tr> | ||
+ | |||
+ | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694053">BBa_K1694053</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-VEGF+RBS+amilCP+Ter<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694054">BBa_K1694054</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-EGFR+RBS+amilCP+Ter<br> | ||
+ | <span><a href="http://parts.igem.org/Part:BBa_K1694055">BBa_K1694055</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+OmpA-anti-HER2+RBS+amilCP+Ter<br> | ||
+ | </td><td></td><td>Chromoprotein is another example of what can be added when making your own probe.<br> | ||
+ | We constructed this part as the P<sub>cons</sub>+RBS+OmpA-scFv+RBS+fluorescent protein+Terminator part. | ||
+ | </td></tr> | ||
+ | |||
+ | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694027">BBa_K1694027</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+FadL-GBP<br> | ||
+ | </td><td></td><td>By ligating the induced promoter (<a href="http://parts.igem.org/Part:BBa_J23110">BBa_J23110</a>), ribosome binding site (<a href="http://parts.igem.org/Part:BBa_B0034">BBa_B0034</a>) and FadL-GBP, we can continuously display the GBP on the <i>E.coli</i> outer membrane.<br> | ||
+ | Then we co-transform the OmpA-scFv parts and this FadL-GBP parts into the same <i>E.coli</i>, hence allowing our <i>E.coli</i> to bind on gold chips and detect antigens simultaneously. | ||
+ | </td></tr> | ||
+ | |||
+ | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694037">BBa_K1694037</a></span><br> | ||
+ | P<sub>cons</sub>+RBS+FadL-GBP+RBS+GFP+Ter<br> | ||
+ | </td><td></td><td>With this part, we can test the GBP function by observing the green fluorescence on the gold chip. Terminator is (<a href="http://parts.igem.org/Part:BBa_B0015">BBa_B0015</a>). | ||
+ | </td></tr> | ||
+ | |||
+ | </table> | ||
</div> | </div> | ||
− | + | ||
− | + | ||
</div> | </div> | ||
+ | <div class="goto" style="background-color:#FCFCDE;"> | ||
+ | <a href="https://2015.igem.org/Team:NCTU_Formosa/Project"><img src="https://static.igem.org/mediawiki/2015/3/3c/%E7%AE%AD%E9%A0%AD1.png"; width=50vw;><br><br>Back to Navigation</a> | ||
</div> | </div> | ||
+ | <div class="goto1" style="background-color:#FCFCDE;"> | ||
+ | <a href="https://2015.igem.org/Team:NCTU_Formosa/Practices"><img src="https://static.igem.org/mediawiki/2015/c/c2/%E7%AE%AD%E9%A0%AD2.png"; width=50vw;><br><br>Go to Practices</a> | ||
+ | </div> | ||
+ | |||
</body> | </body> | ||
</html> | </html> | ||
+ | |||
{{Team:NCTU_Formosa/footer}} | {{Team:NCTU_Formosa/footer}} |
Latest revision as of 03:58, 19 September 2015
Composite Parts
Composite Part
BBa_K1694013 OmpA-anti-VEGF BBa_K1694014 OmpA-anti-EGFR BBa_K1694015 OmpA-anti-HER2 | In order to change the scFv parts easily, we added a NcoI restriction site between OmpA and scFv so that we can change various scFv DNA sequence using the NcoI restriction enzyme. | |
BBa_K1694023 Pcons+RBS+OmpA-anti-VEGF BBa_K1694024 Pcons+RBS+OmpA-anti-EGFR BBa_K1694025 Pcons+RBS+OmpA-anti-HER2 | By ligating the constitutive promoter (BBa_J23101), strong ribosome binding site (BBa_B0034) and Lpp-OmpA-scFv, we were able to display scFv on the E.coli outer membrane continuously.
Having this part, we can co-transform with other parts in order to produce color as the detection signal. In addition, by co-transforming these different types of E.coli with different fluorescence or color as signals, we are able to create a platform which can detect multimarker and consequently achieve combination therapy. | |
BBa_K1694033 Pcons+RBS+OmpA-anti-VEGF+RBS+GFP+Ter BBa_K1694034 Pcons+RBS+OmpA-anti-EGFR+RBS+GFP+Ter BBa_K1694035 Pcons+RBS+OmpA-anti-HER2+RBS+GFP+Ter BBa_K1694044 Pcons+RBS+OmpA-anti-EGFR+RBS+RFP+Ter BBa_K1694045 Pcons+RBS+OmpA-anti-HER2+RBS+BFP+Ter | The most commonly constructing way of composite parts is to ligate the required parts together. We also provide this kind of parts. At the back of the Lpp-OmpA-scFv part, we ligated the weaker ribosome biding site (BBa_B0030), different fluorescent protein and terminator (BBa_J61048) to make it continuously and simultaneously express the fluorescence and the scFv. We used a weak ribosome binding site to ensure that scFv's production will not be affected. | |
BBa_K1694053 Pcons+RBS+OmpA-anti-VEGF+RBS+amilCP+Ter BBa_K1694054 Pcons+RBS+OmpA-anti-EGFR+RBS+amilCP+Ter BBa_K1694055 Pcons+RBS+OmpA-anti-HER2+RBS+amilCP+Ter | Chromoprotein is another example of what can be added when making your own probe. We constructed this part as the Pcons+RBS+OmpA-scFv+RBS+fluorescent protein+Terminator part. | |
BBa_K1694027 Pcons+RBS+FadL-GBP | By ligating the induced promoter (BBa_J23110), ribosome binding site (BBa_B0034) and FadL-GBP, we can continuously display the GBP on the E.coli outer membrane. Then we co-transform the OmpA-scFv parts and this FadL-GBP parts into the same E.coli, hence allowing our E.coli to bind on gold chips and detect antigens simultaneously. | |
BBa_K1694037 Pcons+RBS+FadL-GBP+RBS+GFP+Ter | With this part, we can test the GBP function by observing the green fluorescence on the gold chip. Terminator is (BBa_B0015). |